2015
DOI: 10.1111/aogs.12618
|View full text |Cite
|
Sign up to set email alerts
|

Sex reassignment of transsexual people from a gynecologist's and urologist's perspective

Abstract: Cross-sex hormone treatment of transgender persons is usually uneventful, but hormone-sensitive malignancies of the (reproductive) organs of the natal and new sex (breasts, neovagina) may arise. Sex reassignment surgery impacts on the urodynamics of the reassigned sex. Pathology originating from organ systems of the natal sex may be overlooked in the new sex. In male-to-female transgender individuals, malignant tumors of the breasts and prostate may occur. Neovaginas are constructed with skin or sigmoid. Short… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
24
0
9

Year Published

2017
2017
2022
2022

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 60 publications
(33 citation statements)
references
References 25 publications
(30 reference statements)
0
24
0
9
Order By: Relevance
“…The proposed classification in the present series could be of help for future histopathological investigations of urethral stricture disease. The control specimens with normal urethra came from patients who had undergone sex-correction surgery, and their preoperative treatment with oestradiol may have had an effect on the urethra; however, to the authors' knowledge, no evidence for this exists [23,24]. There are several strengths to the present study, including its prospective design, the consistent follow-up and the fact that the pathologist was blinded to the clinical outcome.…”
Section: Discussionmentioning
confidence: 98%
“…The proposed classification in the present series could be of help for future histopathological investigations of urethral stricture disease. The control specimens with normal urethra came from patients who had undergone sex-correction surgery, and their preoperative treatment with oestradiol may have had an effect on the urethra; however, to the authors' knowledge, no evidence for this exists [23,24]. There are several strengths to the present study, including its prospective design, the consistent follow-up and the fact that the pathologist was blinded to the clinical outcome.…”
Section: Discussionmentioning
confidence: 98%
“…Urinary complications (e.g., fistula, stenosis) following urethra reconstruction are high [3, 4, 6, 23]. …”
Section: Discussionmentioning
confidence: 99%
“…Although none of these studies have been conducted in the transgender population. Both the WPATH and the Endocrine society recommend transfeminine patients follow the current prostate cancer screening guidelines for cis-men with the caveat that 1 ng/ mL should be considered the upper threshold of normal (56,65,66). This guideline should be followed at any point in a patient's transition.…”
Section: Prostate Cancermentioning
confidence: 99%